Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Poststreptococcal reactive arthritis.

E M Ayoub1, H A Majeed

  • 1Department of Pediatrics, University of Florida, Gainesville 32606, USA.

Current Opinion in Rheumatology
|July 26, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Homozygous mutations in LPIN2 are responsible for the syndrome of chronic recurrent multifocal osteomyelitis and congenital dyserythropoietic anaemia (Majeed syndrome).

Journal of medical genetics·2005
Same author

The prevalence of human leukocyte antigen (HLA) DR/DQ/DP alleles in Kuwaiti children with oligoarticular juvenile idiopathic arthritis.

Rheumatology international·2005
Same author

Role of human leukocyte antigen DRB1*0307 and DRB1*0308 in susceptibility to juvenile rheumatoid arthritis.

Clinical and experimental rheumatology·2003
Same author

Prevalence of human leukocyte antigen (HLA) DRB1 alleles in Kuwaiti children with juvenile rheumatoid arthritis.

European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics·2002
Same author

The syndrome of chronic recurrent multifocal osteomyelitis and congenital dyserythropoietic anaemia. Report of a new family and a review.

European journal of pediatrics·2002
Same author

Poststreptococcal reactive arthritis.

The Pediatric infectious disease journal·2001
Same journal

New approaches to the management of cutaneous lupus.

Current opinion in rheumatology·2026
Same journal

"Updates in chronic nonbacterial osteomyelitis: emerging insights across the age spectrum".

Current opinion in rheumatology·2026
Same journal

Difficult-to-treat, complex-to-manage, treatment-refractory spondyloarthritis: semantics or substance?

Current opinion in rheumatology·2026
Same journal

Update on IgA nephropathy: implications for treatment in IgA vasculitis: a guide for rheumatologists.

Current opinion in rheumatology·2026
Same journal

Polyarticular juvenile idiopathic arthritis: insights from genetic studies on disease risk and pathogenesis.

Current opinion in rheumatology·2026
Same journal

Immune dysregulation in children with Down syndrome: clinical implications and emerging therapies.

Current opinion in rheumatology·2026
See all related articles

Poststreptococcal reactive arthritis (PSReA) differs from acute rheumatic fever with distinct clinical and genetic features. Prophylactic antimicrobials are recommended for PSReA patients due to potential late-onset carditis.

Area of Science:

  • Rheumatology
  • Immunology
  • Infectious Diseases

Background:

  • Poststreptococcal reactive arthritis (PSReA) is increasingly recognized.
  • Its distinction from acute rheumatic fever (ARF) is debated.
  • Key differences in latency, joint involvement, and treatment response exist.

Purpose of the Study:

  • To delineate the characteristics of PSReA.
  • To differentiate PSReA from ARF.
  • To provide evidence-based recommendations for PSReA management.

Main Methods:

  • Comparative analysis of clinical features between PSReA and ARF.
  • Review of recent studies on PSReA.
  • Genetic association studies (DRB1*01 in PSReA vs. DRB1*16 in ARF).

Related Experiment Videos

Main Results:

  • PSReA presents with shorter latency, small joint/axial skeleton involvement, and poor NSAID response.
  • PSReA shows a low incidence of carditis but can occur late.
  • Genetic predisposition differs, with DRB1*01 associated with PSReA.

Conclusions:

  • PSReA is a distinct entity from ARF.
  • Recommendations for antimicrobial prophylaxis in PSReA are crucial.
  • Prophylaxis should extend for 5 years or until age 21, whichever is longer, due to late carditis risk.